Overview

Smoking Cessation for People Living With HIV/AIDS

Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
0
Participant gender:
All
Summary
In this proposed study with People Living with HIV/AIDS (PLWHA), we will use a stepped care model called a Sequential Multiple Assignment Randomized Trial (SMART) to examine the efficacy of low- and high-intensity smoking cessation treatments for nicotine dependent PLWHA that incorporate the current standard of care and prize-based contingency management. Intervention will be administered in a community-based HIV integrated care clinic in downtown Detroit, which has the highest prevalence rates of HIV/AIDS and smoking in Michigan. Phase 1 will last 4 weeks, and will involve brief intervention to help participants stop smoking. For phase 2, participants will be assigned to different study arms depending on whether they are Responders (reduced their smoking) or Non-responders (continued to smoke). 1. Phase 1: We hypothesize that brief high-magnitude prize contingency management will result in greater reduction in smoking than standard of care alone. 2. Phase 2a: We hypothesize that non-responders who are assigned to contingency management will be more likely to reduce their smoking throughout treatment and to abstain from smoking at all follow-up points. 3. Phase 2b: We hypothesize that responders who are assigned to monitoring and low-magnitude prize contingency management will be more likely to maintain their reduced or abstinent smoking status at all follow-up time-points.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Wayne State University
Collaborator:
National Institute on Drug Abuse (NIDA)
Treatments:
Bupropion
Criteria
Inclusion Criteria:

1. Age 18 years or older

2. Able to read and understand English

3. Smoke more than 10 cigarettes/day

4. Patient enrolled in the HIV clinic with HIV or AIDS diagnosis

Exclusion Criteria:

1. Are actively suicidal or have uncontrolled manic or psychotic symptoms requiring
immediate care

2. Are in recovery for pathological gambling (PG)

3. Have contraindications for bupropion treatment (e.g., presence of epilepsy or other
seizure disorder, use of monoamine oxidase inhibitors or other antidepressants,
presence of eating disorders or very low weight)

4. Are already participating in other smoking cessation interventions.